Caprion Announces Biomarker Discovery Collaboration with Vertex
Complete the form below to unlock access to ALL audio articles.
Caprion Pharmaceuticals Inc.'s Applied BioMedicine group has announced research collaboration with Vertex Pharmaceuticals Incorporated.
The collaboration will use Caprion's CellCarta® proteomics platform to support clinical biomarker discovery.
Caprion will identify potential pharmacodynamic biomarkers in samples from certain clinical and pre-clinical studies conducted by Vertex.
"Caprion is looking forward to working with Vertex on this clinical biomarker discovery collaboration," noted Dr. Daniel Chelsky, Chief Scientific Officer at Caprion.
"We believe that Caprion's capabilities in the discovery of protein biomarkers may significantly impact development efforts for one or more Vertex compounds."
